Susquehanna International Group, LLP Aeglea Bio Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.11 - $0.46 $3,979 - $16,642	36,179 New	36,179 $16,000
Q4 2022 Feb 14, 2023	BUY	$0.35 - $1.54 $17,830 - $78,452	50,943 New	50,943 $22,000
Q2 2022 Aug 15, 2022	BUY	$0.5 - $2.66 $32,597 - $173,418	65,195 New	65,195 $33,000
Q4 2021 Feb 14, 2022	SELL	$3.5 - $8.42 $39,172 - $94,236	-11,192 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $67,487 - $88,976	11,192 New	11,192 $89,000
Q1 2021 May 17, 2021	SELL	$6.76 - $8.57 $72,068 - $91,364	-10,661 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$7.02 - $9.83 $3,910 - $5,475	-557 Reduced 4.97%	10,661 $84,000
Q3 2020 Nov 16, 2020	BUY	$6.51 - $9.33 $73,029 - $104,663	11,218 New	11,218 $80,000
Q2 2020 Aug 14, 2020	SELL	$4.01 - $11.04 $60,238 - $165,842	-15,022 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$3.51 - $8.48 $52,727 - $127,386	15,022 New	15,022 $70,000
Q4 2019 Feb 14, 2020	SELL	$7.23 - $8.55 $112,983 - $133,610	-15,627 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$6.42 - $9.0 $22,835 - $32,013	3,557 Added 29.47%	15,627 $120,000
Q2 2019 Aug 16, 2019	BUY	$6.1 - $8.78 $73,627 - $105,974	12,070 New	12,070 $83,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.